🚀 VC round data is live in beta, check it out!
Amicus Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Amicus Therapeutics and similar public comparables like Hanmi Pharm, Humanwell Healthcare, Ligand Pharmaceuticals, GSK India and more.
Amicus Therapeutics Overview
About Amicus Therapeutics
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Founded
2002
HQ
Employees
511
Website
Sectors
Financials (LTM)
EV
$5B
Amicus Therapeutics Financials
Amicus Therapeutics reported last 12-month revenue of $671M and EBITDA of $154M.
In the same LTM period, Amicus Therapeutics generated $581M in gross profit, $154M in EBITDA, and $9M in net income.
Revenue (LTM)
Amicus Therapeutics P&L
In the most recent fiscal year, Amicus Therapeutics reported revenue of $634M and EBITDA of $130M.
Amicus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $671M | XXX | $634M | XXX | XXX | XXX |
| Gross Profit | $581M | XXX | $561M | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 89% | XXX | XXX | XXX |
| EBITDA | $154M | XXX | $130M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $9M | XXX | ($27M) | XXX | XXX | XXX |
| Net Margin | 1% | XXX | (4%) | XXX | XXX | XXX |
| Net Debt | — | — | $179M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Amicus Therapeutics Stock Performance
Amicus Therapeutics has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
Amicus Therapeutics' stock price is $14.46.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | 0.0% | XXX | XXX | XXX | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAmicus Therapeutics Valuation Multiples
Amicus Therapeutics trades at 7.0x EV/Revenue multiple, and 30.4x EV/EBITDA.
EV / Revenue (LTM)
Amicus Therapeutics Financial Valuation Multiples
As of April 21, 2026, Amicus Therapeutics has market cap of $5B and EV of $5B.
Equity research analysts estimate Amicus Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Amicus Therapeutics has a P/E ratio of 527.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 7.0x | XXX | 7.4x | XXX | XXX | XXX |
| EV/EBITDA | 30.4x | XXX | 36.0x | XXX | XXX | XXX |
| EV/EBIT | 74.2x | XXX | 136.0x | XXX | XXX | XXX |
| EV/Gross Profit | 8.1x | XXX | 8.4x | XXX | XXX | XXX |
| P/E | 527.2x | XXX | (167.5x) | XXX | XXX | XXX |
| EV/FCF | 22.7x | XXX | 157.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Amicus Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Amicus Therapeutics Margins & Growth Rates
Amicus Therapeutics' revenue in the last 12 month grew by 19%.
Amicus Therapeutics' revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $1.0M for the same period.
Amicus Therapeutics' rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Amicus Therapeutics' rule of X is 75% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Amicus Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 49% | XXX | 61% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 47% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 75% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 19% | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 83% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Amicus Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Amicus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Hanmi Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Humanwell Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Ligand Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| Legend Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Amicus Therapeutics M&A Activity
Amicus Therapeutics acquired XXX companies to date.
Last acquisition by Amicus Therapeutics was on XXXXXXXX, XXXXX. Amicus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Amicus Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAmicus Therapeutics Investment Activity
Amicus Therapeutics invested in XXX companies to date.
Amicus Therapeutics made its latest investment on XXXXXXXX, XXXXX. Amicus Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Amicus Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Amicus Therapeutics
| When was Amicus Therapeutics founded? | Amicus Therapeutics was founded in 2002. |
| Where is Amicus Therapeutics headquartered? | Amicus Therapeutics is headquartered in United States. |
| How many employees does Amicus Therapeutics have? | As of today, Amicus Therapeutics has over 511 employees. |
| Who is the CEO of Amicus Therapeutics? | Amicus Therapeutics' CEO is Bradley L. Campbell. |
| Is Amicus Therapeutics publicly listed? | Yes, Amicus Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Amicus Therapeutics? | Amicus Therapeutics trades under FOLD ticker. |
| When did Amicus Therapeutics go public? | Amicus Therapeutics went public in 2007. |
| Who are competitors of Amicus Therapeutics? | Amicus Therapeutics main competitors are Hanmi Pharm, Humanwell Healthcare, Ligand Pharmaceuticals, GSK India. |
| What is the current market cap of Amicus Therapeutics? | Amicus Therapeutics' current market cap is $5B. |
| What is the current revenue of Amicus Therapeutics? | Amicus Therapeutics' last 12 months revenue is $671M. |
| What is the current revenue growth of Amicus Therapeutics? | Amicus Therapeutics revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Amicus Therapeutics? | Current revenue multiple of Amicus Therapeutics is 7.0x. |
| Is Amicus Therapeutics profitable? | Yes, Amicus Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Amicus Therapeutics? | Amicus Therapeutics' last 12 months EBITDA is $154M. |
| What is Amicus Therapeutics' EBITDA margin? | Amicus Therapeutics' last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Amicus Therapeutics? | Current EBITDA multiple of Amicus Therapeutics is 30.4x. |
| What is the current FCF of Amicus Therapeutics? | Amicus Therapeutics' last 12 months FCF is $207M. |
| What is Amicus Therapeutics' FCF margin? | Amicus Therapeutics' last 12 months FCF margin is 31%. |
| What is the current EV/FCF multiple of Amicus Therapeutics? | Current FCF multiple of Amicus Therapeutics is 22.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.